Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 4/20 | 0.47 |
| ▸ | TRPV4 | Q9HBA0 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CCNK | O75909 | 1/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32670684 | 0.92 | CCR6 (0.45) | CCR6TRPV4CCNKCCNA2CDK2 | |
| SCHEMBL32670540 | 0.89 | CCR6 (0.46) | CCR6TRPV4LMNACCNKCCNA2 | |
| SCHEMBL32670636 | 0.88 | CCR6 (0.47) | CCR6CCNKCCNA2CDK2CDK12 | |
| SCHEMBL32670559 | 0.81 | CCR6 (0.49) | CCR6LMNACCNKCCNA2CDK2 | |
| SCHEMBL32670554 | 0.78 | CCNA2 (0.43) | CCR6LMNACCNKCCNA2CDK2 | |
| SCHEMBL32670630 | 0.78 | CDK2 (0.46) | CCR6LMNACCNKCCNA2CDK2 | |
| SCHEMBL32670649 | 0.78 | JAK2 (0.43) | CCR6LMNACCNKCCNA2CDK2 | |
| SCHEMBL32670652 | 0.77 | NAMPT (0.48) | CCR6CCNKCCNA2CDK2CDK12 | |
| SCHEMBL32670631 | 0.77 | CCR6 (0.42) | CCR6LMNACCNKCCNA2CDK2 | |
| SCHEMBL31155654 | 0.76 | SCN9A (0.54) | CCR6L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034125-A1 | N-PHENYL-1-(PHENYLSULFONYL)PIPERIDIN-4-AMINE DERIVATIVES AS CCR6 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-02-05 | — | — | US | claimed |
| US-20260034125-A1 | N-PHENYL-1-(PHENYLSULFONYL)PIPERIDIN-4-AMINE DERIVATIVES AS CCR6 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034125-A1 | N-PHENYL-1-(PHENYLSULFONYL)PIPERIDIN-4-AMINE DERIVATIVES AS CCR6 INHIBITORS | CCR6, CCR1, CCR4 | CCR6 1/4885TRPV4 1614/4885LMNA 1796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.